These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29390599)

  • 1. [Antibiotic diffusion to central nervous system].
    Cabrera-Maqueda JM; Fuentes Rumí L; Valero López G; Baidez Guerrero AE; García Molina E; Díaz Pérez J; García-Vázquez E
    Rev Esp Quimioter; 2018 Feb; 31(1):1-12. PubMed ID: 29390599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.
    Nau R; Sörgel F; Prange HW
    Clin Pharmacokinet; 1998 Sep; 35(3):223-46. PubMed ID: 9784935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.
    Nau R; Sörgel F; Eiffert H
    Clin Microbiol Rev; 2010 Oct; 23(4):858-83. PubMed ID: 20930076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.
    Sullins AK; Abdel-Rahman SM
    Paediatr Drugs; 2013 Apr; 15(2):93-117. PubMed ID: 23529866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kinetic analysis of the disposition of hydrophilic drugs in the central nervous system (CNS): prediction of the CNS disposition from the transport properties in the blood-brain and blood-cerebrospinal fluid barriers].
    Suzuki H; Sugiyama Y
    Yakugaku Zasshi; 1994 Dec; 114(12):950-71. PubMed ID: 7869236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections.
    Nau R; Seele J; Djukic M; Eiffert H
    Curr Opin Infect Dis; 2018 Feb; 31(1):57-68. PubMed ID: 29293475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-brain barrier drug discovery for central nervous system infections.
    Jong A; Huang SH
    Curr Drug Targets Infect Disord; 2005 Mar; 5(1):65-72. PubMed ID: 15777199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections.
    Luque S; Grau S; Alvarez-Lerma F; Ferrández O; Campillo N; Horcajada JP; Basas M; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Nov; 44(5):409-15. PubMed ID: 25216547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method to predict different mechanisms for blood-brain barrier permeability of CNS activity compounds in Chinese herbs using support vector machine.
    Jiang L; Chen J; He Y; Zhang Y; Li G
    J Bioinform Comput Biol; 2016 Feb; 14(1):1650005. PubMed ID: 26632324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.
    Shen DD; Artru AA; Adkison KK
    Adv Drug Deliv Rev; 2004 Oct; 56(12):1825-57. PubMed ID: 15381336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The penetration of anti-infectives into the central nervous system.
    Kearney BP; Aweeka FT
    Neurol Clin; 1999 Nov; 17(4):883-900. PubMed ID: 10517933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
    Löscher W; Potschka H
    Prog Neurobiol; 2005 May; 76(1):22-76. PubMed ID: 16011870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antibiotics in the treatment of bacterial infections of the central nervous system].
    Doder R; Canak G; Vukadinov J; Turkulov V; Sević S
    Med Pregl; 2010; 63 Suppl 1():22-6. PubMed ID: 21438200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic considerations in the treatment of CNS tumours.
    Motl S; Zhuang Y; Waters CM; Stewart CF
    Clin Pharmacokinet; 2006; 45(9):871-903. PubMed ID: 16928151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic considerations in selecting optimal antibiotic therapy for Mycoplasma pneumoniae encephalitis.
    Cunha BA; Cunha CB
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):631-635. PubMed ID: 30680554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system infections and antimicrobial resistance: an evolving challenge.
    Nau R; Sörgel F; Eiffert H
    Curr Opin Neurol; 2021 Jun; 34(3):456-467. PubMed ID: 33767092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
    Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
    Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.